Literature DB >> 11382406

Effects of riluzole on N-methyl-D-aspartate-induced tyrosine phosphorylation in the rat hippocampus.

A Peyclit1, H Keita, P Juvin, P Derkinderen, F Jardinaud, D Rouellé, J Boczkowski, J M Desmonts, J A Girault, J Mantz.   

Abstract

Since increased tyrosine phosphorylation has been observed in response to brain ischemia, we investigated whether riluzole (an inhibitor of glutamate neurotransmission with neuroprotective properties) affects tyrosine phosphorylation stimulated by N-methyl-D-aspartate (NMDA) in rat hippocampal slices. Riluzole produced an extremely potent concentration-related inhibition of NMDA (1 mM)-stimulated protein tyrosine phosphorylation (IC(50)=0.5+/-0.03 microM, mean+/-S.D.), but failed to affect that evoked by phorbol 12-myristate 13-acetate (PMA, an activator of protein kinase C, 0.1 and 1 microM). These results suggest that inhibition of tyrosine phosphorylation may contribute to the neuroprotective effects of riluzole against excitotoxic injury.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11382406     DOI: 10.1016/s0006-8993(01)02429-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

1.  Riluzole protects against cardiac ischaemia and reperfusion damage via block of the persistent sodium current.

Authors:  S Weiss; D Benoist; E White; W Teng; D A Saint
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 2.  Riluzole in psychiatry: a systematic review of the literature.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-09       Impact factor: 4.481

Review 3.  SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments.

Authors:  Peter I Joyce; Pietro Fratta; Elizabeth M C Fisher; Abraham Acevedo-Arozena
Journal:  Mamm Genome       Date:  2011-06-26       Impact factor: 2.957

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.